Delta V

Delta V is a pre-clinical stage biotechnology company focused on developing a new class of vaccines to prevent respiratory infections, particularly in children. The company utilizes a proprietary alphavirus replicon platform to create highly immunogenic vaccine candidates that aim to provide superior protection compared to traditional methods. Its lead programs target Respiratory Syncytial Virus (RSV) and Parainfluenza Virus 3 (PIV3), addressing significant unmet needs in pediatric infectious disease. Delta V's technology is designed to induce both robust antibody and T-cell responses, potentially offering a more durable and effective immunization strategy.